XML 47 R37.htm IDEA: XBRL DOCUMENT v3.22.2.2
Composition of Other Balance Sheet Items (Tables)
 9 Months Ended
Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of inventories
Inventories, Net
September 30,
2022		December 31,
2021
(unaudited)
Raw materials$11,012 $7,325 
Work in process25,461 45,711 
Finished goods46,692 32,923 
Total$83,165 $85,959 
Schedule of property and equipment
Property and Equipment, Net
September 30,
2022		December 31,
2021
(unaudited)
Lab equipment and furniture$12,207 $12,287 
Leasehold improvements14,023 14,369 
Software1,007 4,776 
Computer equipment1,282 1,944 
Construction-in-progress291 33 
28,810 33,409 
Less accumulated depreciation and amortization(12,938)(16,454)
Property and equipment, net$15,872 $16,955 
Schedule of accounts payable and accrued liabilities
Accounts Payable and Accrued Liabilities
September 30,
2022		December 31,
2021
(unaudited)
Accounts payable$16,015 $9,331 
Accrued professional & marketing fees31,269 26,728 
Accrued compensation16,748 28,068 
Accrued product costs11,129 18,460 
Accrued royalties (1)
11,671 13,821 
Accrued clinical trial costs (2)
6,823 9,125 
Operating lease liabilities, current portion (3)
6,757 6,477 
Other accrued expenses9,890 5,673 
Total$110,302 $117,683 
_______________________________
(1) Refer to Note 16, Commitments and Contingencies.
(2) Includes preclinical and all clinical trial-related costs.
(3) Refer to Note 13, Leases.
Schedule of accrued product returns and rebates
Accrued Product Returns and Rebates
September 30,
2022		December 31,
2021
(unaudited)
Accrued product rebates$119,162 $97,597 
Accrued product returns39,308 35,127 
Total$158,470 $132,724 
Other liabilities
Other Liabilities
September 30,
2022		December 31,
2021
 (unaudited)
Nonrecourse liability related to sale of future royalties, long-term$— $5,977 
Other liabilities10,371 10,403 
Total$10,371 $16,380